New Delhi’s pharmaceutical industry is poised for a major leap forward as the proposed India-US trade deal promises to solidify India’s dominance in the global generics market. Experts highlight that low production costs and a robust manufacturing base have already positioned India as America’s go-to supplier for affordable medicines.
Ketan Jota, Chairman of Zota Healthcare, emphasized in an exclusive interview that India hosts the second-highest number of FDA-approved plants after the US. This infrastructure supports massive exports of generic drugs, life-saving medications, and treatments for chronic conditions straight to American pharmacies.
The trade agreement marks a diplomatic triumph for India, particularly under Prime Minister Narendra Modi’s leadership. For the first time, the US has shown flexibility on tariffs, crafting a balanced deal that benefits both economies. Jota noted that India’s exports to the US primarily include drugs for diabetes, hypertension, and thyroid disorders—ailments with surging demand in the aging US population.
Beyond the US pact, India’s recent trade deal with the European Union eliminates export duties entirely. This zero-duty regime will supercharge pharmaceutical shipments to Europe while fostering technology transfers that enhance India’s manufacturing efficiency. Cheaper production at home means more affordable drugs for Indian patients too.
Overall, these agreements are set to amplify India’s pharma exports, strengthen its global footprint, and deliver tangible benefits to domestic healthcare accessibility. The sector’s future looks brighter than ever, blending economic gains with improved public health outcomes.